ABSTRACT
In order to investigate whether COVID-19 convalescent patients have developed antibodies that may protect from reinfection, we collected sera from COVID-19 convalescent patients approximately 10 weeks after confirmation of COVID-19 by qRT-PCR (group B, n = 25, 11 females, 14 males, age range: 18-70 years, median age 52.2) and included for control purposes sera from subjects obtained before the COVID-19 pandemic (historic control group P, n = 24, 13 females, 11 males, age range: 18-68 years, median age 43.2). Our findings suggest that a natural SARS-CoV-2 infection, similar to that observed previously for rhinovirus (RV) infections,9 does not induce a protective antibody response inhibiting the virus-receptor interaction in all infected patients and therefore underline the urgent need for the development of a SARS-CoV-2 vaccine. The molecular interaction assays could be useful for identifying subjects having developed protective antibodies and for screening candidate vaccines to induce antibodies that inhibit the RBD-ACE2 interaction once they have been validated.
ABSTRACT
The author analyzes the circumstances that caused these changes, which include the state’s measures to combat coronavirus infection (COVID-19), novelties of procedural legislation on the use of digital technologies in judicial disputes, as well as the practice of applying this legislation. The purpose of the study is to establish the validity and expediency of applying certain legislative measures aimed at digitalization of activities related to the implementation of legal assistance by a lawyer to citizens and legal entities. During the research, the following methods were used: general scientific, such as analysis, synthesis, comparison, generalization, historical method;private-scientific: formal-legal, comparative-legal, allowing to consider the digitization issues of advocacy activity. The result of the research is to establish the applicable law to relations concerning the conclusion of a foreign economic contract, the grounds and conditions for recognizing the contract as concluded, and the consequences of not recognizing the fact of concluding an international commercial contract. © 2021, The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.